The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left more money in people’s wallets. Lighter passengers are saving airlines 100 million litres of fuel each year. And billions of people are enjoying a better quality of life, with improvements to their mental and physical health.

The weight-loss drug users and doctors whom The Times spoke to for this ... As powerful anti-obesity drugs become more widely available, companies are repositioning themselves with new products and services. July 18, 2024 With the compounded versions ...

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects

Novo Nordisk posted solid quarterly results Wednesday before the market open.Sales came in at 71.3 billion Danish crowns ($10.3 billion) and diluted earnings per share of DKK 6.12 in the third quarter.

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

What is ageing? Ageing is a highly complex biological process. Our DNA is constantly being broken down and repaired. An imbalance in this process, leading to poor repair of DNA, is one of the hallmarks of ageing.

Experts say as drugs like Ozempic and Wegovy grow in popularity, it presents the chance for fake versions to make their way onto the market.